George J. Christ, PhD has been a Professor of Urology and Physiology & Biophysics as well as Director for Smooth Muscle Biology at Albert Einstein College of Medicine since 1999.
In 1987 he received his Postdoctoral Fellowship into the Department of Pharmacology at Mount Sinai School of Medicine. In 1989 he became an Instructor for the Department of Urology at Albert Einstein College of Medicine in New York. In 1990 he became the Assistant Professor and Director of Basic Research for the Department of Urology at the Albert Einstein College of Medicine in New York. In 1995 he became the Associate Professor and Director of Basic Research, Laboratory of Molecular & Integrative Urology for the Department of Urology at the Albert Einstein College of Medicine and in 1998 he became the Associate Professor for the Department of Physiology & Biophysics at Albert Einstein College of Medicine.
Dr. Christ is currently in the organizing committee for the Society for Basic Urologic Research (SBUR), Basic Science Issues in Men''s Health. He is also a cosultant/Advisor for Bristol-Myers Squibb, Merk, Glaxo and for Ion Channel Innovations, LLC for which he is also the Co-Founder and Directing Member.
PATENTS AWARDED:
"Gene therapy for alleviating erectile dysfunction": U.S. Patent #: 6,150,338 awarded on 11/21/00. Co-Inventors, Jan Geliebter, Ph.D., Jamil Rehman M.D., and Arnold Melman M.D.
"Gene therapy for regulating smooth muscle cell tone": U.S. Patent #: 6,239,117 awarded on May 29, 2001 Co-Inventor: Arnold Melman, M.D. Extends intellectual property claims to cover gene therapy for bladder hyperactivity.
PATENTS PENDING:
"Gene therapy for regulating penile smooth muscle tone", U.S. Patent Application #: 09/532,138. New claim for the use of the Kir6.2 channel subtype gene therapy in the treatment of erectile dysfunction allowed on May 30, 2001.
AWARDS AND HONORS:
Tanagho Prize, Most Innovative New Research, ISIR meeting, Perth, Australia.
Member, Edwin Beer Research Program in Urology Selection Committee of the New York Academy of Medicine
Editorial Board - Current Drug Targets
Tanagho Prize, Most Innovative New Research, ISIR meeting, Amsterdam.
